In what ways can we elevate action around Lp(a) as new risk factor for Cardiovascular Disease?

Résumé fourni par la source

Healthcare trends by PwCIn what ways can we elevate action around Lp(a) as new risk factor for Cardiovascular Disease? www.pwc.be Whitepaper | December 2025Simply put, From momentum to mandate, from declaration to determination, from a plan to prevention.Which steps can be taken to integrate Lp(a) in the Belgian government's CVH plan? 1 How can we gather epidemiological data for Belgium? 2 How to enhance the acceptance of Lp(a) testing as a tool to improve CV prevention in the population?3What must be done to reduce the costs of unnecessary tests to finance Lp(a) testing?4How can we generalize the insights from local initiatives to create CVH passports at the Belgian level? 5How to ensure clear reporting and interpretation of laboratory results to improve patient understanding and willingness to act?

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.